We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Pre-Analytical Stability of Serum Biomarkers for Neurological Disease Investigated

By LabMedica International staff writers
Posted on 01 Apr 2022
Print article
Image: Simoa HD-X Analyzer has a single molecule array platform (Photo courtesy of Quanterix)
Image: Simoa HD-X Analyzer has a single molecule array platform (Photo courtesy of Quanterix)

Blood-based biomarkers are gaining increasing attention in the clinical field of neurological diseases, as they could contribute to accurate monitoring and prediction of disease and treatment outcomes.

Neurofilament-light (NfL), glial fibrillary acidic protein (GFAP) and contactin-1 (CNTN1) are blood-based biomarkers that could contribute to monitoring and prediction of disease and treatment outcomes in neurological diseases. Pre-analytical sample handling might affect results, which could be disease-dependent.

Neurochemists at the Vrije Universiteit Amsterdam (Amsterdam, The Netherlands) tested common handling variations in serum of volunteers as well as in a defined group of patients with multiple sclerosis (pwMS). Sample sets from five pwMS and five volunteers at the outpatient clinic were collected. The team investigated the effect of the following variables: collection tube type, delayed centrifugation, centrifugation temperature, delayed storage after centrifugation and freeze-thawing.

Prior to the NfL and GFAP analyses, serum samples were rapidly thawed, vortexed and centrifuged at 10,000×g for 10 minutes at room temperature. NfL and GFAP were simultaneously analyzed by a Simoa Single Molecule Array platform using the HDx analyzer with the Neurology 2-Plex B multiplex assay (Quanterix, Billerica, MA, USA). Prior to CNTN1 analysis, in a second set of aliquots, serum samples were thawed, vortexed and centrifuged at 10,000×g for 10 minutes at room temperature. The samples were analyzed using the Human contactin-1 Magnetic Luminex Assay (R&D systems, Minneapolis, MN, USA) on a Bio-Plex 200 system (Bio-Rad Laboratories, Hercules, CA, USA).

The scientists reported that for most pre-analytical variables, serum NfL and CNTN1 levels remained unaffected. In the total group, NfL levels increased (121%) after 6 hours of delay at 2–8  °C until centrifugation, while no significant changes were observed after 24 hours delay at room temperature (RT). In pwMS specifically, CNTN1 levels increased from additional freeze-thaw cycles number 2 to 4 (111%–141%), whereas volunteer levels remained stable. GFAP showed good stability for all pre-analytical variables. Serum NfL levels were relatively higher in pwMS (median 6.9 pg/mL, compared to volunteers (4.8 pg/mL). The same was found for serum GFAP levels (pwMS: 60.5 pg/mL; volunteers: 52.1 pg/mL). Serum CNTN1 levels were relatively lower in pwMS (8,103 pg/mL) compared to volunteers (10,671 pg/mL).

The authors concluded that overall, the serum biomarkers tested were relatively unaffected by variations in sample handling. For serum NfL, they recommend storage at RT before centrifugation at 2–8  °C up to 6 hours or at RT up to 24 hours. For serum CNTN1, they advise a maximum of two freeze-thaw cycles. Their results confirm and expand on recently launched consensus standardized operating procedures. The study was published in the journal Clinical Chemistry and Laboratory Medicine.

Related Links:
Vrije Universiteit Amsterdam 
Quanterix 
R&D systems 
Bio-Rad Laboratories 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more